Abstract:To investigate response and survival of radiotherapy (RT) for hepatocellular carcinoma with tumor thrombosis in main portal vein or vena cava, and to analyze prognostic factors. From January 2010 to December 2016, a total of 61 cases of hepatocellular carcinoma with pathological or clinical diagnosis of hepatocellular carcinoma with tumor thrombosis in main portal vein or vena cava were enrolled this study. Main portal vein tumor thrombosis (PVTT) was defined as tumor thrombi was located in main trunk or first branches of portal vein. Fifty-five patients were with PVTT and 4 patients were with venous vein tumor thrombosis alone, respectively. In addition, another 2 patients were with both vein thromboses. All patients had a liver function of Child-Pugh A before radiotherapy. Eighty-five percent of patients (52/61) had a history of hepatitis B, 2% (2/61) had hepatitis C, and 12% (7/61) had no history of hepatitis. Eighty-four percent of patients (51/61) had previously received transcatheter arterial chemoembolization (TACE). Eight patients were treated with concurrent RT and sorafenib. Tumor response was evaluated in one to three months after completion of RT. Survival and prognostic factors were analyzed by Kaplan-Meier method and Cox regression model. The factors included gender, age, history of hepatitis, AFP level before radiotherapy, number of intrahepatic lesions, maximum tumor diameter (MTD), combined TACE, radiotherapy dose were included in analysis of prognosis. All patients were treated with intensity modulated radiotherapy by conventional fraction of 2Gy/f. The median dose was 50Gy (28-66Gy). Response rate (RR, complete response + partial response) was 55.7% when considering all lesions of whole body. In field of RT, RR of the primary tumor was 77.1% and RR of the tumor thrombosis was 83.7%. The 2-year overall survival was 29.9% and median survival time (MST) was 13.6 months. Median time to progression (TTP) was 4.7 months. The 2-year progression free survival of tumor thrombosis was 88.6%. Multivariate analysis showed that the MTD>10cm was an independent poor prognostic factor of TTP (HR, 1.961, 95%CI, 1.034-3.717). TTP in patients with MTD≤10cm and MTD>10cm were 5.0 months and 3.3 months (p=0.026), respectively. However, for MST, combination of TACE (both before or after RT) was an independent favor prognostic factor (HR, 0.184, 95%CI, 0.06-0.565). MST of combination therapy was 15 months, and MST of patients receiving radiotherapy alone was 4 months (p<0.001). Of all patients, grade III or higher liver function damage was 1.6%, and no lethal radiation-induced liver disease occurred. Grade III or higher hematological toxicity was 11.5%. The tumor thrombosis is more sensitive to radiation therapy than the primary tumor. Radiotherapy improves survival by the perfect control of tumor thrombosis. Progression of outside field of RT is primary failure mode for patients with main PVTT. Combination of radiotherapy and TACE is benefit to survivals.

Correlation Between the Expression of P-gp and Efficacy of Chemotherapy Postoperation in Hepatocellular Carcinoma Patients with Tumor Thrombi in Major Portal Vein

EXPRESSION OF P-GLYCOPROTEIN(PGP) AND HEPATITIS B VIRUS X PROTEIN IN THE PRIMARY TUMOR OF LIVER CNACER AND PORTAL VEIN CANCER EMBOLUS AND ITS CLINICAL SIGNIFICANCE

Hepatocellular Carcinoma Associated with Tumor Thrombosis in the Portal Vein: the Effects of Different Treatments.

Evaluation of CT-guided ~(125)I Seed Implantation Combined with Transcatheter Arterial Chemoembolization in Treating Portal Vein Tumor Thrombus Associated with Hepatocellular Carcinoma

Chemotherapeutic Perfusion of Portal Vein after Tumor Thrombectomy and Hepatectomy Benefits Patients with Advanced Hepatocellular Carcinoma: A Propensity Score‐matched Survival Analysis

Efficacy of Different Treatment Strategies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

The expression of PDGFRα in HCC and association with prognosis

Transarterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Prognostic Factors in a Single-Center Study of 188 Patients.

CLINICAL SIGNIFICANCE OF P-GLYCOPROTEIN EXPRESSION IN METASTATIC BREAST CARCINOMA

Surgical therapy and prognostic analysis for patients of terminal hepatocellular carcinoma with portal vein thrombus

Expression of Platelet-Derived Endothelial Cell Growth Factor and Vascular Endothelial Growth Factor in Hepatocellular Carcinoma and Portal Vein Tumor Thrombus

Neoadjuvant-Based Triple Therapy for Hepatocellular Carcinoma with Type I/II Portal Vein Tumor Thrombosis

Transarterial Chemoembolization for Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombosis.

Efficacy of Postoperative Adjuvant Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients With Microscopic Portal Vein Invasion

Postoperative Adjuvant Trans-Arterial Chemoembolization for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus

Influencing Factors for Prognosis of Patients with Hepatocellular Carcinoma Complicated with Portal Vein Tumor Thrombus after Surgical Treatment

Postoperative adjuvant immunotherapy and molecular targeted therapy for patients of hepatocellular carcinoma with portal vein tumor thrombus after hepatectomy: a propensity score matching study

The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus.

Clinical Study on the Sensitivity Test Guided Hepato-Arterial/portal-vein Chemotherapy in Patients with Unresectable Hepatocellar Carcinoma

[Comparison of the Results and Therapies for Hepatocellular Carcinoma with Tumor Thrombosis in Portal Vein].

Efficacy And Prognosis Of Radiotherapy For Hepatocellular Carcinoma With Tumor Thrombosis In Main Portal Vein Or/And Vena Cava